Study selection
Studies were selected if they were randomised, double blind, controlled trials in which any type of antibiotic treatment (topical, systemic, or a combination) was compared with placebo in patients with acute bacterial conjunctivitis.
Data extraction
Both reviewers independently assessed the quality of studies. 1 reviewer extracted data on participants, disease definition, interventions, and outcomes. Outcomes were clinical remission (defined as clinical cure or clinically significant improvement) and microbiological remission (defined as pathogen eradication or reduction). The other reviewer checked the accuracy of data extraction.
Main results
3 studies (527 patients) met the selection criteria. 1 study included children (1 mo to 18 y of age), 1 included adults, and 1 did not specify the age of patients. Antibiotic treatment included polymixin 10 000 U/g plus bacitracin 500 U/g, and 0.3% norfloxacin plus 0.0025% benzalkonium chloride preservative. 1 study presented combined results for 2 studies that compared ciprofloxacin with placebo and ciprofloxacin with tobramycin. Follow up ranged from 2 to 10 days. Pooled results showed that antibiotics increased microbiological and clinical remission rates at 2 to 5 days and at 6 to 10 days (table) . No serious adverse events were reported in the antibiotic or placebo groups.
Conclusion
In patients with acute bacterial conjunctivitis, most remit spontaneously, but antibiotic treatment further increases clinical and microbiological remission rates. Recently, clinicians have been encouraged to reduce the prescribing of antibiotics for other minor self limiting illnesses (ie, sore throat and otitis media) because of problems with antibiotic resistance.
Antibiotics (AB) v placebo for acute bacterial conjunctivitis*
The review by Sheikh and Hurwitz used rigorous methods to summarise the limited evidence on acute bacterial conjunctivitis. The trials are from secondary care and thus may not be directly applicable to primary care settings. All the trials used microbiologically confirmed cases, which means that the number needed to treat using clinical diagnosis of patients will probably be substantially higher.
Although the review shows improved clinical and microbiological remission rates with antibiotics, it must be remembered that this condition is self limiting. Symptoms are usually mild, and the review shows that 64% of patients are cured at day 2 to 5 without treatment. No serious adverse effects were seen in these studies, which suggests that sightthreatening complications are rare. The effect of a quicker cure in reducing secondary cases of conjunctivitis has not been assessed.
Further trials are needed to clarify whether it is appropriate to prescribe antibiotics for all patients to achieve a few days of reduction in symptoms in a minority of patients. In the meantime, as discussed by the authors, it might be worth considering a delayed prescription strategy (ie, prescribing only for those cases that have not resolved by day 5).
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